PT  - JOURNAL ARTICLE
AU  - Chokesuwattanaskul, Susama
AU  - Alarcon, Michele Fresneda
AU  - Mangalakumaran, Sangeetha
AU  - Grosman, Rudi
AU  - Cross, Andrew L
AU  - Chapman, Elinor A
AU  - Mason, David
AU  - Moots, Robert J
AU  - Phelan, Marie M
AU  - Wright, Helen L
TI  - Metabolic profiling of rheumatoid arthritis neutrophils reveals altered energy metabolism that is not affected by JAK inhibition
AID  - 10.1101/2022.05.30.22275773
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.30.22275773
4099  - http://medrxiv.org/content/early/2022/05/31/2022.05.30.22275773.short
4100  - http://medrxiv.org/content/early/2022/05/31/2022.05.30.22275773.full
AB  - Neutrophils play a key role in the pathophysiology of rheumatoid arthritis (RA) where release of ROS and proteases directly causes damage to joints and tissues. Neutrophil function can be modulated by Janus Kinase (JAK) inhibitor drugs, including tofacitinib and baricitinib, which are clinically effective treatments for RA. However clinical trials have reported increased infection rates and transient neutropenia during therapy. The subtle differences in the mode of action, efficacy and safety of JAK inhibitors has been the primary research topic of many clinical trials and systematic reviews, to provide a more precise and targeted treatment to patients. The aim of this study was to determine both the differences in the metabolome of neutrophils from healthy controls and people with RA, and the effect of different JAK inhibitors on the metabolome of healthy and RA neutrophils. Isolated neutrophils from healthy controls (HC) (n=6) and people with RA (n=7) were incubated with baricitinib, tofacitinib or a pan-JAK inhibitor (all 200ng/mL) for 2h. Metabolites were extracted and 1H nuclear magnetic resonance (NMR) was applied to study the metabolic changes. Multivariate analyses and machine learning models showed a divergent metabolic pattern in RA neutrophils compared to HC at 0h (F1 score = 86.7%) driven by energy metabolites (ATP, ADP, GTP and glucose). No difference was observed in the neutrophil metabolome when treated with JAK inhibitors. However, JAK inhibitors significantly inhibited ROS production and baricitinib decreased NET production (p<0.05). Bacterial killing was not impaired by JAK inhibitors, indicating the effect of JAK inhibitors on neutrophils can inhibit joint damage in RA without impairing host defence. This study highlights altered energy metabolism in RA neutrophils which may explain the cause of their dysregulation in inflammatory disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a Pfizer Aspire IIR award [Grant No W1213850]. MFA was funded by a Versus Arthritis and Masonic Charitable Fund PhD scholarship [Grant no 22193]. SM was funded by the University of Liverpool School of Life Sciences. EAC was funded by theWellcome Trust [200605/Z/16/Z]. HLW was funded by a Versus Arthritis Career Development Fellowship [Grant No 21430].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the University of Liverpool Central University Research Ethics Committee C for HC (Ref RETH000956 approval date 9th December 2015), and NRES Committee North West (Greater Manchester West, UK) for RA patients (Ref 11/NW/0206 approval date 20th May 2011).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMetabolomics data have been deposited to the EMBL-EBI MetaboLights database with the identifier MTBLS4766. The complete dataset can be accessed here: https://www.ebi.ac.uk/metabolights/MTBLS4766. https://www.ebi.ac.uk/metabolights/MTBLS4766 ACRAmerican College of RheumatologyDHR123Dihydrorhodamine-123DMARDDisease-modifying anti-rheumatic drugfMLPf-Met-Leu-PheGM-CSFGranulocyte/macrophage-colony stimulating factorJAKJanus KinaseJAKiJanus kinase inhibitorNADPHNicotinamide adenine dinucleotide phosphateNETNeutrophil extracellular trapNMRnuclear magnetic resonancePMAPhorbol 12-myristate 13-acetateRARheumatoid arthritisROSReactive Oxygen SpeciesSTATSignal transducers and activators of transcriptionTNFαTumour necrosis factor alpha